0001191638-14-001090.txt : 20140801 0001191638-14-001090.hdr.sgml : 20140801 20140801082403 ACCESSION NUMBER: 0001191638-14-001090 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140801 FILED AS OF DATE: 20140801 DATE AS OF CHANGE: 20140801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 141008136 BUSINESS ADDRESS: STREET 1: 2 KINGDOM STREET - LEGAL DEPARTMENT CITY: LONDON STATE: X0 ZIP: W2 6BD BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 2 KINGDOM STREET - LEGAL DEPARTMENT CITY: LONDON STATE: X0 ZIP: W2 6BD FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 azn201408016k.htm DIRECTOR/PDMR SHAREHOLDING azn201408016k.htm



FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of  August 2014

Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 
 


Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
 
On 1 August 2014, Leif Johansson, a Director of the Company notified us that, on 1 August 2014, he sold and purchased AstraZeneca PLC Ordinary Shares of $0.25 each.

As a result of these transactions, Mr Johansson has increased his total interest by 6,000 AstraZeneca shares.

Mr Johansson holds some of his AstraZeneca shares in pension arrangements in Sweden. One part of these arrangements has closed, resulting in the sale of shares. In order to maintain his interest in AstraZeneca shares, Mr Johansson has reinvested the sale proceeds.

Details of the sale and purchase are as follows:

1,000 shares sold at a price of SEK 503.00 per share.
1,000 shares purchased at a price of SEK 503.00 per share.

In addition, on 1 August 2014, Mr Johansson purchased a further 6,000 shares at a price of SEK 502.95 per share.

 
On 31 July 2014, certain other Directors of the Company notified us that, on 31 July 2014, they purchased AstraZeneca PLC Ordinary Shares of $0.25 each, as follows:
 
Name of Director
Number of shares purchased
Purchase price
Geneviève Berger
300
4324p
Shriti Vadera
3,500
4328p
John Varley
3,500
4370p


A C N Kemp
Company Secretary
1 August 2014
 
 

 
SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 01 August 2014
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary